Latest News and Press Releases

Agreement incorporates TYMLOS® and abaloparatide-TDConsideration includes upfront payment, milestones based on clinical, regulatory and commercial progression, as well as royaltiesKey first step in...

BOSTON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) announced today that Machelle Sanders and Dr. Andrew C. von Eschenbach have joined the...

Continued growth in net new patients for the month of November 2020Company is on-track for record quarter in net revenue for TYMLOS-SCResearch Agreement reached with MGH in October 2020Hired Head of...

TYMLOS® U.S. net sales of $50 million with 8% year-over-year growth; Total Revenues of $78 millionQ3 commercial pivot to focus on high risk fracture segment is gaining traction: Net New U.S. Patients...

Completed enrollment in 3 pivotal clinical trials; multiple data read outs in Q4 2021Released meaningful abaloparatide histomorphometry data at recent ASBMR meetingCompleted two business development...

WALTHAM, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its third quarter financial results on Thursday, November 5, 2020. The Company...

WALTHAM, Mass., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced that Peter A. Schwartzman is joining the company as Vice President in...

Business development step enables molecule to move forwardProgram progression will be at no financial risk to RadiusReinforces Radius’ focus on execution of core business WALTHAM, Mass., Oct. 01,...

Target enrollment milestone reached in the Phase 3 EMERALD studyLife cycle planning advancing in parallel with current Phase 3 monotherapy program WALTHAM, Mass. and FLORENCE, Italy, Sept. 24,...

Organizational Change within Finance FunctionCreates Capital, Strategy & Transactions Group WALTHAM, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”)...